Source: biOasis Technologies Inc. and reported by http://www.marketwatch.com/
The biOasis Neuro-Oncology Program
biOasis has completed efficacy and other tests using Her2+ brain tumor animal models using its lead BBB delivery vectors melanotransferrin (MTf) and melanotransferrin-peptide(MTfp) to deliver the anti-cancer drug, trastuzumab (TZM) across the blood-brain barrier (BBB). Fusion proteins comprised of the cancer drug trastuzumab (TZM or Herceptin) and MTf (MTf-TZM) or MTfp (MTfp-TZM) were used. The purpose of these studies was to answer specific questions and provide data relating to taking MTfp-TZM into clinical trials. As a result of the combined studies and with the benefit of the full collection of data, the biOasis Board of Directors supports moving MTfp-TZM to an IND and into clinical trials.
The recent results revealed that MTfp-TZM showed increased activity against Her2+ brain tumors when compared to other Transcend/trastuzumab conjugates that biOasis has previously tested. MTfp-TZM reduced the size and number of brain tumors in the animal models and showed improved activity levels outside the brain compared to TZM alone. Statistically significant increased animal survival rates were also observed compared to the controls. An additional dose titration study confirmed tolerance at levels equal to that of current dosing in humans.
Read more: http://www.marketwatch.com/story/bioasis-provides-scientific-updates-on-its-transcend-programs-2015-05-12-19173050